EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Comparison of Sex-Specific Treatment Outcomes in Clinical Trials and Subsequent Real-World Data on Systemic Therapies for Urothelial Carcinoma: A Systematic Review

Marie Christine Roesch, Lea Sophie Lütje, Marten Müller, Axel S. Merseburger, Daniar Osmonov, Nils Gilbert

Aktuelle Urologie · 2026-08-04

DOI: 10.1055/a-2897-1443 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background/Context Treatment outcomes after systemic cancer therapies exhibit sex-specific differences. Real-world data do not necessarily reflect the results of randomized clinical trials (RCTs). Objective To compare sex-specific outcomes between RCTs and subsequent real-world data in patients with urothelial cancer (UC) receiving systemic therapies. Methods A systematic literature search on systemic therapies for UC was conducted in Embase, PubMed, MEDLINE, and Scopus up to February 2025. Eligible studies included phase II/III trials, RCTs, prospective non-interventional studies, retrospective studies, and case series. Extracted parameters comprised hazard ratios for overall survival and progression-free survival (or disease-free survival for adjuvant therapies), sex-specific enrollment rates, and discontinuation rates due to adverse effects. This review is registered with PROSPERO and was conducted in accordance with PRISMA guidelines. Results A total of 52 articles were included. The proportion of female patients enrolled in UC RCTs did not reflect epidemiologic data, and only a few real-world studies reached the expected benchmark. The following approval studies showed a survival benefit for men compared with women: JAVELIN Bladder 100 (Avelumab), Keynote 045 (Pembrolizumab), EV-301 (Enfortumab Vedotin), CheckMate 901 (Gemcitabine + Cisplatin + Nivolumab), and CheckMate 274 (adjuvant Nivolumab). Only a limited number of real-world studies reported sex-specific outcome analyses, and none demonstrated a clear benefit for either sex. No sex-specific toxicity analyses were published. Conclusion Several approval studies investigating therapies for urothelial cancer suggest a survival benefit for male patients. However, this finding was not confirmed in real-world data. Female patients remain underrepresented in approval trials for UC, and sex-specific toxicity analyses are lacking. Such analyses should be mandatory in future RCTs.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →